BACKGROUND: Therapies for heart failure (HF) with a low ejection fraction (EF) have delayed disease progression and prolonged survival, but the implications of these therapies on the end stages of HF have not been examined. METHODS AND RESULTS: Patients seen by the Brigham and Women's cardiomyopathy service with an EF < or =35%, at least 1 outpatient visit or at least 30 days of follow-up who died between January 1, 2000, and October 20, 2003, were evaluated retrospectively. Of the 160 patients who died since 2000, 80 (50%) were outpatients. In the 6 months before death, 93% of patients had New York Heart Association (NYHA) class III or IV symptoms. The NYHA class, clinical characteristics, medications, and comorbidities differed little between inpatient and outpatient deaths. Renal insufficiency and hyponatremia were worse in the months preceding death than at the time of death (creatinine: 3.2 versus 2.3 mg/dL, P < .0001; sodium: 128 versus 135 mmol/L, P < .0001, respectively). Death was considered sudden in only 21% of patients. CONCLUSION: Deaths in the current era of HF management occur in patients with long-standing HF characterized by biventricular dysfunction and advanced symptoms. Most deaths are heralded by hyponatremia, acute on chronic renal insufficiency, and frequent hospitalizations.
BACKGROUND: Therapies for heart failure (HF) with a low ejection fraction (EF) have delayed disease progression and prolonged survival, but the implications of these therapies on the end stages of HF have not been examined. METHODS AND RESULTS:Patients seen by the Brigham and Women's cardiomyopathy service with an EF < or =35%, at least 1 outpatient visit or at least 30 days of follow-up who died between January 1, 2000, and October 20, 2003, were evaluated retrospectively. Of the 160 patients who died since 2000, 80 (50%) were outpatients. In the 6 months before death, 93% of patients had New York Heart Association (NYHA) class III or IV symptoms. The NYHA class, clinical characteristics, medications, and comorbidities differed little between inpatient and outpatient deaths. Renal insufficiency and hyponatremia were worse in the months preceding death than at the time of death (creatinine: 3.2 versus 2.3 mg/dL, P < .0001; sodium: 128 versus 135 mmol/L, P < .0001, respectively). Death was considered sudden in only 21% of patients. CONCLUSION: Deaths in the current era of HF management occur in patients with long-standing HF characterized by biventricular dysfunction and advanced symptoms. Most deaths are heralded by hyponatremia, acute on chronic renal insufficiency, and frequent hospitalizations.
Authors: Douglas S Lee; Philimon Gona; Irene Albano; Martin G Larson; Emelia J Benjamin; Daniel Levy; William B Kannel; Ramachandran S Vasan Journal: Circ Heart Fail Date: 2010-11-11 Impact factor: 8.790
Authors: Luis A Sánchez; Carlos Enrique Guerrero-Beltrán; Andrea M Cordero-Reyes; Gerardo García-Rivas; Guillermo Torre-Amione Journal: Methodist Debakey Cardiovasc J Date: 2013 Oct-Dec
Authors: Soko Setoguchi; Robert J Glynn; Margaret Stedman; Carol M Flavell; Raisa Levin; Lynne Warner Stevenson Journal: Am Heart J Date: 2010-07 Impact factor: 4.749
Authors: Katherine C Wu; Robert G Weiss; David R Thiemann; Kakuya Kitagawa; André Schmidt; Darshan Dalal; Shenghan Lai; David A Bluemke; Gary Gerstenblith; Eduardo Marbán; Gordon F Tomaselli; João A C Lima Journal: J Am Coll Cardiol Date: 2008-06-24 Impact factor: 24.094
Authors: Paul R Forfia; Stephen C Mathai; Micah R Fisher; Traci Housten-Harris; Anna R Hemnes; Hunter C Champion; Reda E Girgis; Paul M Hassoun Journal: Am J Respir Crit Care Med Date: 2008-03-20 Impact factor: 21.405
Authors: Arise G S Galil; Hélady S Pinheiro; Alfredo Chaoubah; Darcília M N Costa; Marcus G Bastos Journal: BMC Nephrol Date: 2009-10-21 Impact factor: 2.388